CD38 and plasma cell myeloma: Perhaps, the situation in myeloma is similar: high levels of CD38 may be beneficial for myeloma cell survival and conversely the low levels of expression imposed by treatment with daratumumab may render the myeloma cells more vulnerable to other anti-myeloma treatments.